Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31696858 | 0.93 | CTSB (0.52) | CTSBKMT2AKCNJ1MEN1POLB | |
| SCHEMBL27837565 | 0.87 | ALDH1A1 (0.53) | KMT2AKCNJ1MEN1LMNASMN1; SMN2 | |
| SCHEMBL32662599 | 0.81 | CYP1A2 (0.46) | KMT2AMEN1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5857285 | 0.81 | ALDH1A1 (0.52) | KMT2AKCNJ1MEN1LMNASMN1; SMN2 | |
| SCHEMBL27837694 | 0.80 | ALDH1A1 (0.52) | KMT2AKCNJ1MEN1LMNASMN1; SMN2 | |
| SCHEMBL28171036 | 0.79 | LMNA (0.56) | CTSBKMT2AKCNJ1MEN1POLB | |
| SCHEMBL9086867 | 0.78 | POLB (0.51) | KMT2APOLBSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL27573003 | 0.78 | TSHR (0.46) | KMT2AMEN1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5147272 | 0.76 | CYP1A2 (0.42) | KMT2AMEN1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL20299855 | 0.76 | BCL9 (0.44) | KMT2AMEN1LMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441723-B2 | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations | RIGEL PHARMACEUTICALS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441723-B2 | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations | IRAK1, IRAK3, IRAK2 | CTSB 3400/4885KMT2A 1863/4885KCNJ1 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.